Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | P4HB | P07237 | 2/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29965999 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TRPA1LMNAALOX5MAPK1 | |
| SCHEMBL18345851 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TRPA1LMNAALOX5MAPK1 | |
| SCHEMBL28264132 | 0.83 | EPAS1 (0.36) | EPAS1 | |
| SCHEMBL77140 | 0.81 | EPAS1 (0.37) | EPAS1 | |
| SCHEMBL29472378 | 0.81 | EPAS1 (0.37) | EPAS1 | |
| SCHEMBL3920843 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TRPA1LMNAALOX5MAPK1 | |
| SCHEMBL3920837 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TRPA1LMNAALOX5MAPK1 | |
| SCHEMBL18345536 | 0.79 | ALDH1A1 (0.35) | ALDH1A1TRPA1LMNAALOX5MAPK1 | |
| SCHEMBL18345538 | 0.79 | ALDH1A1 (0.35) | ALDH1A1TRPA1LMNAALOX5MAPK1 | |
| SCHEMBL28963596 | 0.75 | ALDH1A1 (0.41) | ALDH1A1TRPA1LMNAALOX5MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851433-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-11851433-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-26 | — | — | US | disclosed |
| EP-3625234-B1 | HEXAHYDROPYRAZOLO [1,2-A] DIAZEPINONES AND RELATED HETEROCYCLES AS INHIBITORS OF RIP-1 KINASE | DENALI THERAPEUTICS INC (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230203027-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION | 2023-06-29 | — | — | US | disclosed |
| US-20230203027-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023083847-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-05-19 | — | — | WO | disclosed |
| CN-108602809-B | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1(RIPK 1) | 戴纳立制药公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20220024938-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11174262-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210332058-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3313837-B1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | DENALI THERAPEUTICS INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10570129-B2 | Carboline antiparasitics | ZOETIS SERVICES LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20200031822-A1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-20190300537-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20180353480-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) | APTUIT (VERONA) S.R.L. (IT) | 2018-12-13 | — | — | US | disclosed |
| WO-2018107060-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| EP-3313837-A1 | CARBOLINE ANTIPARASITICS | Zoetis Services LLC (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2017096301-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK 1) | DENALI THERAPEUTICS INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| WO-2016209635-A1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203027-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK2, RIPK3 | ALDH1A1 4315/4885TRPA1 4816/4885LMNA 3512/4885 |
| US-20180353480-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | ALDH1A1 4555/4885TRPA1 4105/4885LMNA 2362/4885 |
| US-20210332058-A1 | Compounds, Compositions and Methods | BAX, CASP3, CASP8 | ALDH1A1 3491/4885TRPA1 1254/4885LMNA 107/4885 |
| US-20220024938-A1 | Compounds, Compositions and Methods | BAX, CASP3, CASP8 | ALDH1A1 3491/4885TRPA1 1254/4885LMNA 107/4885 |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | ALDH1A1 4555/4885TRPA1 4105/4885LMNA 2362/4885 |
| US-20190300537-A1 | Compounds, Compositions and Methods | BAX, CASP3, CASP8 | ALDH1A1 3491/4885TRPA1 1254/4885LMNA 107/4885 |
| US-10570129-B2 | Carboline antiparasitics | ADRA1D, DRD1, CHRM1 | ALDH1A1 381/4885TRPA1 2577/4885LMNA 2992/4885 |
| US-11174262-B2 | Compounds, compositions and methods | BAX, CASP3, CASP8 | ALDH1A1 3491/4885TRPA1 1254/4885LMNA 107/4885 |
| US-20200031822-A1 | CARBOLINE ANTIPARASITICS | DRD1, ADRA1D, DRD2 | ALDH1A1 334/4885TRPA1 2709/4885LMNA 3352/4885 |
| US-11851433-B2 | Compounds, compositions and methods | BAX, CASP3, CASP8 | ALDH1A1 3491/4885TRPA1 1254/4885LMNA 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.